管理肺动脉高血压与心肺合并疾病的管理
Steeve Provencher1, Vicky Mai1, Sebastien Bonnet1
1Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, QC, Canada; Pulmonary Hypertension Research Group, Université Laval, Quebec City, QC, Canada; Department of Medicine, Université Laval, Quebec City, QC, Canada.
肺动脉高血压 (PAH) 越来越多地被诊断为伴随性疾病. 目前的PAH治疗可能不适合心力衰竭或肺部疾病表型患者,需要进一步研究.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 内部医学 内部医学
背景情况:
- 肺动脉高血压 (PAH) 的诊断和治疗因并发症而复杂化.
- 越来越多的PAH患者出现心力衰竭或肺部疾病表型.
- 现有的PAH治疗指南缺乏具有重大并发症的患者的数据.
研究的目的:
- 审查有关在患有并发症的患者中管理PAH的文献.
- 讨论与心肺相关疾病相关的PAH目前的治疗方法.
- 突出了对这种患者群体进行进一步研究的需要.
主要方法:
- 关于PAH和并发症的相关研究的文献综述.
- 对PAH当前治疗策略的分析.
- 讨论新出现的PAH表型.
主要成果:
- 越来越多的PAH患者出现并发症,包括心力衰竭与保存的喷射分数样和肺表型.
- 目前对PAH治疗的证据在患有并发症的患者中有限.
- 对伴随疾病的PAH的最佳治疗策略在很大程度上是未知的.
结论:
- 对于患有并发症的患者,PAH管理需要量身定制的方法.
- 进一步的临床试验对于在复杂病例中建立基于证据的PAH治疗方法至关重要.
- 了解不同的PAH表型对于有效的患者护理至关重要.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
COPD: Management Using Bronchodilators and Corticosteroids


